FundedStartupsDaily / HealthTech / Celosia Therapeutics

Celosia Therapeutics raises A$2M

Celosia Therapeutics announced a Debt / Non-dilutive round of A$2M on 18 November 2026. The company operates in HealthTech and is based in Australia. It was founded by Dr Kathryn Sunn, CEO. Announced today.

Raised
A$2M
Stage
Debt / Non-dilutive
Industry
HealthTech
Country
Australia

Founder

Dr Kathryn Sunn
CEO, Celosia Therapeutics
LinkedIn not available

Outreach angles

  • -Dr Kathryn Sunn leads Celosia, a Macquarie University spinout built on research by professors Lars Ittner and Yazi Ke.
  • -In March, Celosia dosed the first participant in a phase 1b trial of its lead programme, CTx1000, in sporadic ALS.
  • -Celosia won the maximum A$2M grant, the largest in the first round of the NSW Emerging Technology Commercialisation Fund, to develop a second MND gene therapy.

Signals

DebtDeep TechHealthcareRegulated Industry

Round details

Company: Celosia Therapeutics
Domain: celosiatherapeutics
Amount: A$2M
Stage: Debt / Non-dilutive
Industry: HealthTech
Country: Australia
Announced: 18 November 2026
Source: announcement

Other HealthTech raises

Recently funded in Australia